AlphaStem
Industry: Therapeutics for cardiovascular disease
AlphaStem is exploring cell-based therapy for cardiovascular disease. The core technology is based on research by Emory University’s Dr. Young-sup Yoon, who identified novel, specialized angio-vasculogenic cells that can be used in stem cell therapy for patients with peripheral vascular disease.
The cells Dr. Yoon identified are derived from human peripheral blood and bone marrow, and they are distinguished by a unique expression of CD31 on the cell surface. These CD31-positive cells offer special capacity to form blood vessels and regenerate tissues in models of cardiovascular disease.
Cardiovascular disease is the number one cause of death in the U.S. The American Heart Association estimates that by 2030, the cost of treating cardiovascular disease will reach $818 billion.
